Kumar Kulabhusan Prabir, Hussain Babar, Yüce Meral
Department of Biotechnology, Gangadhar Meher University, Sambalpur 768001, India.
Faculty of Life Sciences, University of Central Punjab, Lahore 54000, Pakistan.
Pharmaceutics. 2020 Jul 9;12(7):646. doi: 10.3390/pharmaceutics12070646.
Aptamers are synthetic single-stranded DNA or RNA sequences selected from combinatorial oligonucleotide libraries through the well-known in vitro selection and iteration process, SELEX. The last three decades have witnessed a sudden boom in aptamer research, owing to their unique characteristics, like high specificity and binding affinity, low immunogenicity and toxicity, and ease in synthesis with negligible batch-to-batch variation. Aptamers can specifically bind to the targets ranging from small molecules to complex structures, making them suitable for a myriad of diagnostic and therapeutic applications. In analytical scenarios, aptamers are used as molecular probes instead of antibodies. They have the potential in the detection of biomarkers, microorganisms, viral agents, environmental pollutants, or pathogens. For therapeutic purposes, aptamers can be further engineered with chemical stabilization and modification techniques, thus expanding their serum half-life and shelf life. A vast number of antagonistic aptamers or aptamer-based conjugates have been discovered so far through the in vitro selection procedure. However, the aptamers face several challenges for its successful clinical translation, and only particular aptamers have reached the marketplace so far. Aptamer research is still in a growing stage, and a deeper understanding of nucleic acid chemistry, target interaction, tissue distribution, and pharmacokinetics is required. In this review, we discussed aptamers in the current diagnostics and theranostics applications, while addressing the challenges associated with them. The report also sheds light on the implementation of aptamer conjugates for diagnostic purposes and, finally, the therapeutic aptamers under clinical investigation, challenges therein, and their future directions.
适体是通过著名的体外筛选和迭代过程——指数富集的配体系统进化技术(SELEX),从组合寡核苷酸文库中筛选出来的合成单链DNA或RNA序列。在过去三十年里,适体研究突然兴起,这得益于其独特的特性,如高特异性和结合亲和力、低免疫原性和毒性,以及易于合成且批次间差异可忽略不计。适体可以特异性结合从小分子到复杂结构的各种靶标,使其适用于无数的诊断和治疗应用。在分析场景中,适体被用作分子探针而非抗体。它们在检测生物标志物、微生物、病毒制剂、环境污染物或病原体方面具有潜力。出于治疗目的,适体可以通过化学稳定和修饰技术进一步改造,从而延长其血清半衰期和保质期。到目前为止,通过体外筛选程序已经发现了大量拮抗适体或基于适体的缀合物。然而,适体在成功临床转化上面临若干挑战,到目前为止只有特定的适体进入了市场。适体研究仍处于发展阶段,需要对核酸化学、靶标相互作用、组织分布和药代动力学有更深入的了解。在这篇综述中,我们讨论了适体在当前诊断和治疗诊断学应用中的情况,同时阐述了与之相关的挑战。本报告还阐明了适体缀合物在诊断目的中的应用,最后介绍了正在进行临床研究的治疗性适体及其面临的挑战和未来方向。